Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1/2 trial.
Garcia-Manero, Guillermo
Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1/2 trial. [electronic resource] - The Lancet. Haematology Jun 2019 - e317-e327 p. digital
Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial
2352-3026
10.1016/S2352-3026(19)30029-8 doi
Adolescent
Adult
Aged
Aged, 80 and over
Antineoplastic Agents--adverse effects
Azacitidine--adverse effects
Dose-Response Relationship, Drug
Female
Humans
Male
Middle Aged
Myelodysplastic Syndromes--drug therapy
Neutropenia--etiology
Severity of Illness Index
Survival Rate
Thrombocytopenia--etiology
Treatment Outcome
Young Adult
Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1/2 trial. [electronic resource] - The Lancet. Haematology Jun 2019 - e317-e327 p. digital
Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial
2352-3026
10.1016/S2352-3026(19)30029-8 doi
Adolescent
Adult
Aged
Aged, 80 and over
Antineoplastic Agents--adverse effects
Azacitidine--adverse effects
Dose-Response Relationship, Drug
Female
Humans
Male
Middle Aged
Myelodysplastic Syndromes--drug therapy
Neutropenia--etiology
Severity of Illness Index
Survival Rate
Thrombocytopenia--etiology
Treatment Outcome
Young Adult